Skip to main content
Fig. 1 | BMC Gastroenterology

Fig. 1

From: Reduced mortality and morbidity associated with metformin and SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cirrhosis

Fig. 1

Cohort Creation for Metformin versus Metformin-SGLT2-I Groups; Cohort 1 included patients who were initiators of metformin without any instance of SGLT2-I in their electronic medical record (EMR). Cohort 2 inclusion included metformin initiators and additional SGLT2-I therapy. Both cohorts consisted of patients starting on March 01, 2014 to December 13, 2022. T2DM, Type 2 Diabetes Mellitus; SGLT2-I, Sodium glucose cotransporter-2 inhibitors; TIPS, Transvenous Intrahepatic Portosystemic Shunt; HCC, Hepatocellular Carcinoma

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us